Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
AssigneeSmithKline Beecham p.I.c.
InventorsJeffrey Roger Granett, Hamish Ross, Jaikrishna Patel, Robin Kevin John Price, Paul Nigel Wray
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising Compound (1), characterised in that the composition comprises 2 to 12 mg of Compound (1) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.
Claims22
A pharmaceutical composition comprising 5-[4-[2-(N-methyl -N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter ‘Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (1) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor.
A process for preparing a pharmaceutical composition comprising 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier therefor, which process comprises admixing 2 to 12 mg of the dione in a pharmaceutically acceptable form and the pharmaceutically acceptable carrier.
A process for preparing a pharmaceutical composition of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:
- (i) preparing a first composition comprising the dione in a pharmaceutically acceptable form and a first pharmaceutically acceptable carrier;
- (ii) admixing the first composition with a second pharmaceutically acceptable carrier to provide the required composition of dione and optionally thereafter formulating the composition produced into an administerable form.
A composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier, wherein the composition is a pharmaceutically acceptable, pre-administration composition.
Dependencies are inferred from the claim text.